Gilead Sciences, Inc. (NASDAQ:GILD) insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Friday, September 1st. The stock was sold at an average price of $83.11, for a total transaction of $6,094,705.63. Following the completion of the sale, the insider now owns 2,996,766 shares of the company’s stock, valued at approximately $249,061,222.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded up 2.321% during midday trading on Thursday, reaching $84.875. 4,599,434 shares of the company’s stock were exchanged. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $85.05. The company has a market capitalization of $110.84 billion, a PE ratio of 9.219 and a beta of 1.19. The firm has a 50-day moving average of $75.14 and a 200-day moving average of $69.48.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same period in the prior year, the business posted $3.08 earnings per share. Equities analysts expect that Gilead Sciences, Inc. will post $8.74 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.51%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

ILLEGAL ACTIVITY WARNING: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/09/07/gilead-sciences-inc-gild-insider-john-c-martin-sells-73333-shares-of-stock.html.

A number of analysts recently issued reports on the stock. BidaskClub lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Argus upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target for the company in a research note on Thursday, August 31st. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price target for the company. in a research note on Monday, August 28th. Cowen and Company restated an “outperform” rating and issued a $90.00 price target on shares of Gilead Sciences in a research note on Wednesday, July 5th. Finally, Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $73.00 to $81.00 and gave the stock a “market perform” rating in a research note on Wednesday. Eleven research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $83.06.

Institutional investors have recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. raised its stake in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 267 shares during the last quarter. Penserra Capital Management LLC raised its stake in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the last quarter. Webster Bank N. A. raised its stake in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 624 shares during the last quarter. Finally, American Beacon Advisors Inc. purchased a new stake in shares of Gilead Sciences in the first quarter worth approximately $143,000. 74.05% of the stock is owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.